Show simple item record

dc.contributor.authorMartin, Matthew
dc.contributor.authorMarais, Richard
dc.date.accessioned2012-12-13T14:46:25Z
dc.date.available2012-12-13T14:46:25Z
dc.date.issued2012-07-20
dc.identifier.citationMetformin: a diabetes drug for cancer, or a cancer drug for diabetics? 2012, 30 (21):2698-700 J Clin Oncolen_GB
dc.identifier.issn1527-7755
dc.identifier.pmid22565000
dc.identifier.doi10.1200/JCO.2012.42.1677
dc.identifier.urihttp://hdl.handle.net/10541/262493
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subject.meshAntineoplastic Agents
dc.subject.meshBody Mass Index
dc.subject.meshBreast Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshDiabetes Mellitus
dc.subject.meshEnzyme Activation
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHypoglycemic Agents
dc.subject.meshMale
dc.subject.meshMetformin
dc.subject.meshNeoplasms
dc.subject.meshProtein Kinases
dc.titleMetformin: a diabetes drug for cancer, or a cancer drug for diabetics?en
dc.typeArticleen
dc.contributor.departmentThe Paterson Institute for Cancer Research, Wilmslow Rd, Manchester, UK.en_GB
dc.identifier.journalJournal of Clinical Oncologyen_GB


This item appears in the following Collection(s)

Show simple item record